Axsome Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. 

CEO
Herriott Tabuteau
CEOHerriott Tabuteau
Employees
683
Employees683
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2012
Founded2012
Employees
683
Employees683

AXSM Key Statistics

Market cap
8.79B
Market cap8.79B
Price-Earnings ratio
-37.30
Price-Earnings ratio-37.30
Dividend yield
Dividend yield
Average volume
1.10M
Average volume1.10M
High today
$177.95
High today$177.95
Low today
$173.67
Low today$173.67
Open price
$177.95
Open price$177.95
Volume
582.46K
Volume582.46K
52 Week high
$184.40
52 Week high$184.40
52 Week low
$84.54
52 Week low$84.54

Stock Snapshot

As of today, Axsome Therapeutics(AXSM) shares are valued at $174.33. The company's market cap stands at 8.79B, with a P/E ratio of -37.30.

On 2026-01-13, Axsome Therapeutics(AXSM) stock moved within a range of $173.67 to $177.95. With shares now at $174.33, the stock is trading +0.4% above its intraday low and -2.0% below the session's peak.

Trading volume for Axsome Therapeutics(AXSM) stock has reached 582.46K, versus its average volume of 1.1M.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $184.40 and a low of $84.54.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $184.40 and a low of $84.54.

AXSM News

Nasdaq 2d
Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65%

(RTTNews) - Axsome Therapeutics, Inc. (AXSM) said, based on preliminary financial information, Axsome expects total product revenue to be approximately $196.0 m...

Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65%
TipRanks 2d
Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth

Claim 70% Off TipRanks Premium Axsome Therapeutics ( (AXSM) ) has provided an announcement. On January 12, 2026, Axsome Therapeutics reported preliminary, una...

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .